China Immunotech (beijing) Biotechnology Co., Ltd.
Clinical trials sponsored by China Immunotech (beijing) Biotechnology Co., Ltd., explained in plain language.
-
Experimental cell therapy targets severe autoimmune diseases in early trial
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and whether the treat…
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New cell therapy hopes to tame autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of these specially designed cells. The main goal is …
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
Experimental cell therapy targets severe autoimmune Flare-Ups
Disease control Recruiting nowThis early-stage study tests a new cell treatment called YTS109 in 18 adults with autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard therapies. Participants receive a single infusion of these specially designed cells. The main goal is to che…
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 08, 2026 13:11 UTC
-
Experimental cell therapy aims to tame Hard-to-Treat autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and vasculitis that have not responded to standard treatments. Participants receive a single infusion of these specially engineered cells. The main goal is to che…
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 03, 2026 12:06 UTC